Legal showdown over Mifepristone comes amid growing state-federal tensions…
The Trump administration has signaled it will defend the Food and Drug Administration (FDA) in a closely watched legal battle over Mifepristone, the abortion pill used in over half of U.S. terminations. The move comes after the Supreme Court agreed in 2024 to review access restrictions on the drug in the wake of the Dobbs decision, which ended federal constitutional protections for abortion.
The Department of Justice on Monday said a lawsuit against the Food and Drug Administration seeking to sharply restrict the abortion pill mifepristone should be dismissed, continuing the position of the Biden administration.
In a court filing, the Trump administration argued Idaho, Missouri and Kansas have no ties to Amarillo, Texas, where the lawsuit was filed. The states are free to file in their own districts, the DOJ said.
“Aside from this litigation, the States do not dispute that their claims have no connection to the Northern District of Texas,” the DOJ wrote. “The states cannot keep alive a lawsuit in which the original plaintiffs were held to lack standing, those plaintiffs have now voluntarily dismissed their claims, and the States’ own claims have no connection to this District.”
The states did not file their own lawsuit but instead were granted the ability to intervene in a lawsuit first filed in 2022 by a group of anti-abortion physicians and medical associations.
Background on the Drug at the Center of the Dispute
Approved by the FDA in 2000, Mifepristone is commonly used in medication abortions but has raised safety questions among critics. The Mayo Clinic and other sources have flagged risks such as incomplete abortions requiring surgical intervention. Notably, there is limited safety data for patients under age 17, with no pediatric-specific studies available — fueling concerns about potential long-term health impacts for young users.
FDA’s Role and the Scope of the Lawsuit
The lawsuit aims to challenge the FDA’s decision-making authority and could have implications beyond abortion policy. Pro-life advocates argue that the agency did not sufficiently evaluate the risks associated with Mifepristone when loosening restrictions. However, the FDA maintains it followed established protocols and defends its ability to regulate drug safety — not insurance coverage or pricing, where access gaps often emerge.
What’s at Stake
This case reflects a broader shift in the post-Dobbs legal environment, where state-level restrictions and federal regulatory authority are on a collision course. If the lawsuit succeeds, it could undercut the FDA’s independence and open the door to further legal challenges against other drugs, especially those tied to contentious political issues.
READ NEXT: Recent Homelessness Spike Fueled By One Major Issue
